These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 21837532)

  • 21. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma.
    Hamidov Z; Altendorf-Hofmann A; Chen Y; Settmacher U; Petersen I; Knösel T
    J Clin Pathol; 2011 Nov; 64(11):990-4. PubMed ID: 21725043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
    Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
    Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
    Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
    Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
    Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
    Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
    Nitori N; Ino Y; Nakanishi Y; Yamada T; Honda K; Yanagihara K; Kosuge T; Kanai Y; Kitajima M; Hirohashi S
    Clin Cancer Res; 2005 Apr; 11(7):2531-9. PubMed ID: 15814630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
    Zhu Z; Xu Y; Du J; Tan J; Jiao H
    J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Wen Z; Liao Q; Zhao J; Hu Y; You L; Lu Z; Jia C; Wei Y; Zhao Y
    Ann Surg Oncol; 2014 Jan; 21(1):125-32. PubMed ID: 24132627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced α-dystroglycan expression correlates with shortened patient survival in pancreatic cancer.
    Jiang X; Rieder S; Giese NA; Friess H; Michalski CW; Kleeff J
    J Surg Res; 2011 Nov; 171(1):120-6. PubMed ID: 20338590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma.
    Jamieson NB; Mohamed M; Oien KA; Foulis AK; Dickson EJ; Imrie CW; Carter CR; McKay CJ; McMillan DC
    Ann Surg Oncol; 2012 Oct; 19(11):3581-90. PubMed ID: 22555345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and significance of leukemia inhibitory factor in human pancreatic cancer].
    Peng F; Zhou J; Sheng W; Zhang D; Dong M
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):90-5. PubMed ID: 24721346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
    Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
    J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma.
    Ben QW; Wang JC; Liu J; Zhu Y; Yuan F; Yao WY; Yuan YZ
    Ann Surg Oncol; 2010 Aug; 17(8):2213-21. PubMed ID: 20162456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis.
    Guweidhi A; Kleeff J; Giese N; El Fitori J; Ketterer K; Giese T; Büchler MW; Korc M; Friess H
    Carcinogenesis; 2004 Sep; 25(9):1575-85. PubMed ID: 15073049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
    Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
    J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
    Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
    J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Localization of the human hedgehog-interacting protein (Hip) in the normal and diseased pancreas.
    Kayed H; Kleeff J; Esposito I; Giese T; Keleg S; Giese N; Büchler MW; Friess H
    Mol Carcinog; 2005 Apr; 42(4):183-92. PubMed ID: 15754313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
    Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
    J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma.
    Vizio B; Mauri FA; Prati A; Trivedi P; Giacobino A; Novarino A; Satolli MA; Ciuffreda L; Camandona M; Gasparri G; Bellone G
    Oncol Rep; 2012 Jan; 27(1):69-76. PubMed ID: 21922151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.